These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9193736)

  • 21. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
    Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
    J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. beta-Endorphin, cortisol, and prolactin in serum of schizophrenic patients during long-term neuroleptic treatment and after withdrawal: relationships to psychopathology.
    Naber D; Albus M; Muller F; Burke H; Welter D; Ackenheil M; Hippius H
    Psychopharmacol Bull; 1982 Oct; 18(4):224-6. PubMed ID: 6130563
    [No Abstract]   [Full Text] [Related]  

  • 23. Serotonin function in schizophrenia: effects of meta-chlorophenylpiperazine in schizophrenic patients and healthy subjects.
    Kahn RS; Siever LJ; Gabriel S; Amin F; Stern RG; DuMont K; Apter S; Davidson M
    Psychiatry Res; 1992 Jul; 43(1):1-12. PubMed ID: 1332094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine's anxiogenic effects.
    Klein E; Zohar J; Geraci MF; Murphy DL; Uhde TW
    Biol Psychiatry; 1991 Nov; 30(10):973-84. PubMed ID: 1756202
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuroendocrine effects of M-chlorophenylpiperazine, a serotonin agonist, in humans.
    Mueller EA; Murphy DL; Sunderland T
    J Clin Endocrinol Metab; 1985 Dec; 61(6):1179-84. PubMed ID: 4055985
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serotonin receptor responsivity in schizophrenia.
    Kahn RS; Davidson M
    Int Clin Psychopharmacol; 1993 Nov; 8 Suppl 2():47-51. PubMed ID: 7911140
    [No Abstract]   [Full Text] [Related]  

  • 27. Neuroendocrine and behavioral responses to intravenous m-chlorophenylpiperazine (mCPP) in depressed patients and healthy comparison subjects.
    Anand A; Charney DS; Delgado PL; McDougle CJ; Heninger GR; Price LH
    Am J Psychiatry; 1994 Nov; 151(11):1626-30. PubMed ID: 7943451
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients.
    Abel KM; O'Keane V; Murray RM
    Br J Psychiatry; 1996 Jan; 168(1):57-60. PubMed ID: 8770429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dissociable hormonal, cognitive and mood responses to neuroendocrine challenge: evidence for receptor-specific serotonergic dysregulation in depressed mood.
    Riedel WJ; Klaassen T; Griez E; Honig A; Menheere PP; van Praag HM
    Neuropsychopharmacology; 2002 Mar; 26(3):358-67. PubMed ID: 11850150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Psychopharmacologic approaches to schizophrenic psychoses].
    Giacardy-Paty M; Soubrouillard C; Blin O
    Encephale; 1995 Jun; 21 Spec No 3():3-8. PubMed ID: 7628339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serotonin dysfunction in pathological gamblers: increased prolactin response to oral m-CPP versus placebo.
    Pallanti S; Bernardi S; Quercioli L; DeCaria C; Hollander E
    CNS Spectr; 2006 Dec; 11(12):956-64. PubMed ID: 17146409
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuroendocrine responses in chronic schizophrenia. Evidence for serotonergic dysfunction.
    Lerer B; Ran A; Blacker M; Silver H; Weller MP; Drummer D; Ebstein B; Calev A
    Schizophr Res; 1988; 1(6):405-10. PubMed ID: 3154528
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of meta-chlorophenylpiperazine on neuroendocrine and behavioral responses in male schizophrenic patients and normal volunteers.
    Maes M; Meltzer HY
    Psychiatry Res; 1996 Oct; 64(3):147-59. PubMed ID: 8944393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perspectives on the role of serotonergic mechanisms in the pharmacology of schizophrenia.
    Seibyl JP
    J Psychopharmacol; 1997; 11(2):188-9. PubMed ID: 9208382
    [No Abstract]   [Full Text] [Related]  

  • 35. Beneficial effects of nalmefene augmentation in neuroleptic-stabilized schizophrenic patients.
    Rapaport MH; Wolkowitz O; Kelsoe JR; Pato C; Konicki PE; Pickar D
    Neuropsychopharmacology; 1993 Sep; 9(2):111-5. PubMed ID: 8105790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of olanzapine treatment on m-chlorophenylpiperazine-induced hormone release in schizophrenia.
    Scheepers FE; Gespen de Wied CC; Kahn RS
    J Clin Psychopharmacol; 2001 Dec; 21(6):575-82. PubMed ID: 11763004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Serotonin function and treatment response to clozapine in schizophrenic patients.
    Kahn RS; Davidson M; Siever L; Gabriel S; Apter S; Davis KL
    Am J Psychiatry; 1993 Sep; 150(9):1337-42. PubMed ID: 8394651
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Responses to mCPP stimulation in depressed patients.
    Thakore JH
    Am J Psychiatry; 1995 Dec; 152(12):1833-4; author reply 1834-5. PubMed ID: 8526261
    [No Abstract]   [Full Text] [Related]  

  • 39. Studies of serotonin function in anorexia nervosa.
    Brewerton TD; Jimerson DC
    Psychiatry Res; 1996 Apr; 62(1):31-42. PubMed ID: 8739113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The blunted plasma cortisol response to apomorphine and its relationship to treatment response in patients with schizophrenia.
    Meltzer HY; Lee MA; Jayathilake K
    Neuropsychopharmacology; 2001 Mar; 24(3):278-90. PubMed ID: 11166518
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.